| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c18c23e10cf7058ff84e67cb5aa0c0cd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1048 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01T1-163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-585 |
| filingDate |
1989-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93f83c12a609a377afa41bb61ad2fbe0 |
| publicationDate |
1991-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H03141230-A |
| titleOfInvention |
Injection composition for therapy of human tumor |
| abstract |
PURPOSE: To obtain the subject composition containing an antibody highly specific to a tumor-related marker radiolabeled with a radiotherapeutically effective radioisotope and capable of concentrating the radioisotope at a tumor-growing site. n CONSTITUTION: This injection composition contains (A) at least one kind of marker-specific antibody or antibody fragment radiolabeled with a tumor- reducing effective amount of a pharmacologically inert and radiotherapeutically effective radioisotope (e.g. iodine or rhenium isotope) specific to a tumor marker and (B) a pharmaceutically acceptable injection carrier. The tumor marker includes a cancer fetal antigen which is a cell surface marker, an alpha fetal protein which is an intracellular marker, and a human chorionic gonadotropin. An antibody having at least 70% of specific immunoreactivity and ≤15% of cross-reactivity is used as the antibody. n COPYRIGHT: (C)1991,JPO |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-19980038203-A |
| priorityDate |
1980-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |